Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Total Current Liabilities (2016 - 2025)

Immucell (ICCC) has disclosed Total Current Liabilities for 16 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 10.48% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2025, down 10.48%, and an annual FY2024 reading of $4.4 million, up 5.12% over the prior year.
  • Total Current Liabilities was $4.0 million for Q3 2025 at Immucell, down from $4.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $4.6 million in Q2 2024 and bottomed at $2.0 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $3.4 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities fell 14.47% in 2021, then skyrocketed 53.52% in 2023.
  • Year by year, Total Current Liabilities stood at $2.5 million in 2021, then rose by 21.21% to $3.1 million in 2022, then skyrocketed by 36.63% to $4.2 million in 2023, then increased by 5.12% to $4.4 million in 2024, then dropped by 9.39% to $4.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for ICCC at $4.0 million in Q3 2025, $4.4 million in Q2 2025, and $3.9 million in Q1 2025.